Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 22, 2019 11:54 ET | Source: ONL Therapeutics

ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204 into First-In-Human Clinical Study

ANN ARBOR, Mich., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
August 22, 2019 07:00 ET | Source: ONL Therapeutics

ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204 into First-In-Human Clinical Study

ANN ARBOR, Mich., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
June 18, 2019 07:00 ET | Source: ONL Therapeutics

ONL Therapeutics Names Industry Veteran as CEO as Company Prepares for First in Human Clinical Trials

ANN ARBOR, Mich., June 18, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving vision in a range of retinal diseases, today...
May 17, 2017 08:05 ET | Source: ONL Therapeutics

ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases

ANN ARBOR, MI--(Marketwired - May 17, 2017) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today...
March 28, 2017 08:05 ET | Source: ONL Therapeutics

ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team

ANN ARBOR, MI--(Marketwired - Mar 28, 2017) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today...
March 21, 2017 08:05 ET | Source: ONL Therapeutics

ONL Therapeutics Receives Nearly $1.0 Million Grant from National Eye Institute for Continued Advancement of ONL1204 Program

ANN ARBOR, MI--(Marketwired - Mar 21, 2017) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced...
February 11, 2016 08:05 ET | Source: ONL Therapeutics

ONL Therapeutics Receives Orphan Drug Designation for ONL1204 for Treatment of Retinal Detachment From FDA

ANN ARBOR, MI--(Marketwired - Feb 11, 2016) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced...
October 29, 2015 08:05 ET | Source: ONL Therapeutics

ONL Therapeutics to Present at the 2015 Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting

ANN ARBOR, MI--(Marketwired - Oct 29, 2015) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced...
October 14, 2015 08:05 ET | Source: ONL Therapeutics

ONL Therapeutics Announces Formation of Scientific Advisory Board

ANN ARBOR, MI--(Marketwired - Oct 14, 2015) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today...
June 15, 2015 08:00 ET | Source: ONL Therapeutics

ONL Therapeutics Provides Update on Novel Photoreceptor Protection Platform for Retinal Diseases

ANN ARBOR, MI--(Marketwired - Jun 15, 2015) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today provided an...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right